New short radiation course aims to stop returning prostate cancer

NCT ID NCT05746806

Ongoing Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing a new way to treat prostate cancer that returns after the prostate has been removed. It combines a very short course of highly targeted radiation (just 5 sessions) with 6 months of hormone therapy. The goal is to see if this approach can control the cancer with fewer side effects than standard treatments. The study involves 36 men whose cancer has come back only in the prostate bed, as shown by advanced imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ultrahypofractionated salvage radiotherapy (targeted radiation in 5 sessions) plus short-term androgen deprivation therapy (hormone therapy for 6 months)
What this could lead to: If successful, this approach could offer a more precise, shorter treatment option for men whose prostate cancer returns after surgery, potentially delaying further progression.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. Side effects from radiation and hormone therapy, such as fatigue or urinary issues, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PROSTATE CANCER

Contacts and locations

Locations

Inselgruppe AG, Inselspital

Bern, 3010, Switzerland
Istituto Oncologico della Svizzera Italiana-Ente Ospedaliero Cantonale (IOSI-EOC)

Bellinzona, 6500, Switzerland
Kantonsspital Winterthur, Klinik für Radio-Onkologie

Winterthur, 8401, Switzerland
Universitätsspital Basel

Basel, 4031, Switzerland
Universitätsspital Zürich, Klinik für Radio-Onkologie

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.